Psilocybin

Generic Name
Psilocybin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C12H17N2O4P
CAS Number
520-52-5
Unique Ingredient Identifier
2RV7212BP0
Background

Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain

First Posted Date
2022-08-18
Last Posted Date
2024-10-29
Lead Sponsor
Emory University
Target Recruit Count
11
Registration Number
NCT05506982
Locations
🇺🇸

Brain Health Center at Executive Park, Atlanta, Georgia, United States

🇺🇸

Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

Phase 2
Completed
Conditions
Anorexia Nervosa
Interventions
Drug: Psilocybin
First Posted Date
2022-08-01
Last Posted Date
2024-12-04
Lead Sponsor
COMPASS Pathways
Target Recruit Count
32
Registration Number
NCT05481736
Locations
🇺🇸

Altman Clinical and Translational Research Institute, San Diego, California, United States

🇺🇸

Sheppard Pratt Health System, Baltimore, Maryland, United States

🇺🇸

Dell Medical School, Austin, Texas, United States

and more 2 locations

An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics

First Posted Date
2022-07-28
Last Posted Date
2023-08-15
Lead Sponsor
Usona Institute
Target Recruit Count
60
Registration Number
NCT05478278
Locations
🇺🇸

Altasciences Clinical Kansas, Inc, Overland Park, Kansas, United States

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Phase 2
Recruiting
Conditions
Tobacco Use Disorder
Interventions
Drug: Psilocybin
Drug: Niacin
First Posted Date
2022-07-11
Last Posted Date
2024-11-27
Lead Sponsor
Johns Hopkins University
Target Recruit Count
66
Registration Number
NCT05452772
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Sheppard Pratt, Baltimore, Maryland, United States

🇺🇸

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

and more 1 locations

Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder

Phase 2
Recruiting
Conditions
Alcohol Use Disorder
Interventions
Drug: Ketamine
Drug: Psilocybin
First Posted Date
2022-06-16
Last Posted Date
2024-03-26
Lead Sponsor
Peggy C Nopoulos
Target Recruit Count
20
Registration Number
NCT05421065
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder

Phase 2
Recruiting
Conditions
Alcohol Use Disorder
Interventions
Drug: Psilocybin
Drug: Maltodextrin
First Posted Date
2022-06-13
Last Posted Date
2023-08-24
Lead Sponsor
Anders Fink-Jensen, MD, DMSci
Target Recruit Count
90
Registration Number
NCT05416229
Locations
🇩🇰

Psychiatric Center Copenhagen, Frederiksberg Hospital, Frederiksberg, Denmark

Pragmatic Trial of Psilocybin Therapy in Palliative Care

Phase 2
Not yet recruiting
Conditions
Demoralization
Interventions
Drug: Psilocybin
Drug: Ketamine
First Posted Date
2022-06-03
Last Posted Date
2024-10-09
Lead Sponsor
Charles S. Grob, M.D.
Target Recruit Count
100
Registration Number
NCT05403086

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

First Posted Date
2022-06-01
Last Posted Date
2024-07-31
Lead Sponsor
University of Chicago
Target Recruit Count
10
Registration Number
NCT05399498
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Psilocybin Versus Ketamine in Treatment-Resistant Depression

First Posted Date
2022-05-20
Last Posted Date
2022-05-20
Lead Sponsor
National Institute of Mental Health, Czech Republic
Target Recruit Count
60
Registration Number
NCT05383313
Locations
🇨🇿

National Institute of Mental Health, Klecany, Czechia

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

First Posted Date
2022-05-19
Last Posted Date
2024-01-24
Lead Sponsor
Massachusetts General Hospital
Registration Number
NCT05381974
Locations
🇺🇸

Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy